Use of the GLP-1R agonists and DPP-4 inhibitors also enable the clinician to minimize the risk of some of the complications commonly encountered when treating patients with T2DM, such as hypoglycemia and weight gain. Here, GLP1R is linked to type 2 diabetes mellitus.